Integrated Biopharma (INBP) Stock Price

Integrated Biopharma Price

OTC·CLOSED
0.19
-0.0025 (-1.32 %)
Market closed

Revenue at Integrated Biopharma has contracted by 0.3% per year over the past 19 years to 54.35 M USD. Earnings per share have declined at 19.6% per year over the last 19 years. For Integrated Biopharma, the net margin of 1.5% is down versus 12.6% a few years ago. The stock trades about 25% above its 52-week low.

Integrated Biopharma stock price

Access this data via the Eulerpool API

Integrated Biopharma business model & stock analysis

Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry. Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company. In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School. In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others. Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements. Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases. One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies. Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany. Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China. Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate." Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry.

Frequently asked questions about Integrated Biopharma

Integrated Biopharma Inc is a leading biopharmaceutical company that specializes in the development, manufacturing, and distribution of innovative healthcare products. The company operates through two main segments: Contract Manufacturing and Nutraceuticals. Integrated Biopharma Inc's business model revolves around providing contract manufacturing services to pharmaceutical and healthcare companies, offering a wide range of services including product development, formulation, packaging, and quality control. Additionally, the company also manufactures and markets a diverse portfolio of nutraceutical products that promote health and well-being. Integrated Biopharma Inc's commitment to quality, innovation, and customer satisfaction has made it a trusted partner in the biopharmaceutical industry.

Integrated Biopharma Inc is primarily active in the healthcare and pharmaceutical industries.

The main competitors of Integrated Biopharma Inc in the market include prominent companies such as Pfizer, Johnson & Johnson, Amgen, Roche Holding AG, and Novartis AG. These competitors are major players in the biopharmaceutical industry and compete with Integrated Biopharma Inc in areas including drug research and development, manufacturing, marketing, distribution, and sales.

Integrated Biopharma Inc is a reputable company with a rich history and background. Established in [year], Integrated Biopharma Inc has emerged as a leading player in the [industry] sector. The company specializes in [specific products or services] and has consistently delivered exceptional results. With a commitment to innovation and high-quality standards, Integrated Biopharma Inc has successfully developed and commercialized numerous breakthrough products. Over the years, the company has built strong partnerships, expanded its global presence, and garnered a solid reputation for reliability and customer satisfaction. Integrated Biopharma Inc continues to strive for excellence, driving growth and success in the market.

Integrated Biopharma Inc, a leading biotechnology company, has achieved several significant milestones. The company has successfully developed and commercialized a range of innovative pharmaceutical and dietary supplement products. Integrated Biopharma Inc has made notable strides in research and development, driving advancements in various therapeutic areas. With a focus on ensuring quality and safety, the company has obtained regulatory approvals for its products, further enhancing its market presence. Additionally, their commitment to continuous innovation and strategic partnerships has supported the company's growth and expanded its global reach. Integrated Biopharma Inc continues to make strides in the healthcare industry, establishing itself as a trusted and successful player.

Integrated Biopharma Inc is primarily present in countries and regions across the globe. With its global reach, the company has a strong presence in the United States, Europe, Asia, and other international markets. This diversified geographical presence allows Integrated Biopharma Inc to leverage various opportunities and cater to a wide customer base. By operating in multiple countries and regions, the company is able to tap into different market dynamics, expand its distribution network, and effectively serve its customers worldwide. Integrated Biopharma Inc's international presence is testament to its commitment to global growth and the delivery of its high-quality products and services.

Integrated Biopharma Inc represents values of innovation, scientific excellence, and commitment to improving human health. With a focus on the development, manufacturing, and marketing of high-quality nutraceutical and pharmaceutical products, the company prioritizes research-driven approaches to deliver effective solutions. Integrated Biopharma Inc embraces a corporate philosophy centered on enhancing wellness and longevity through its diverse portfolio of products. By constantly pushing the boundaries of biotechnology and prioritizing customer satisfaction, the company has established itself as a trusted name in the industry. Integrated Biopharma Inc's dedication to cutting-edge science and ethical business practices makes it a leader in the field of biopharmaceuticals.

Converted at the current exchange rate, the Integrated Biopharma share trades at 0.16 EUR (0.19 USD).

Integrated Biopharma Inc. is a diversified company specializing in the discovery, development, and marketing of innovative products in the fields of health, nutrition, and wellness. The company was founded in 1979 and is headquartered in New York, USA. The business model of Integrated Biopharma Inc. is based on various divisions, including the sale of raw materials, research and development, manufacturing of dietary supplements, and licensing of patents and technologies. The company offers a wide range of products, including natural raw materials such as herbs, extracts, and powders used in the manufacturing of dietary supplements and pharmaceutical products. Some of its well-known products include probiotics that improve gut health and digestion, as well as vitamins and minerals that help support a healthy lifestyle. Another division of Integrated Biopharma Inc. is research and development of new products. The company has its own research laboratory where innovative technologies and processes are developed to enhance the efficacy and safety of dietary supplements and drugs. The manufacturing of dietary supplements and pharmaceutical products is another important division of Integrated Biopharma Inc. The company operates its own production facilities and has extensive experience in producing products in compliance with the high-quality standards of the Food and Drug Administration (FDA). In addition to these divisions, Integrated Biopharma Inc. also offers licensing of patents and technologies. The company holds a variety of patents on innovative technologies in the fields of health, nutrition, and wellness and offers them for licensing. The business model of Integrated Biopharma Inc. is based on long-term relationships with customers and partners built on trust and quality. The company emphasizes collaboration with customers in product development and provides comprehensive customer service to ensure customer satisfaction. In summary, the business model of Integrated Biopharma Inc. is focused on the discovery, development, and marketing of innovative products in the fields of health, nutrition, and wellness. The company has divisions including raw materials, research and development, manufacturing of dietary supplements, and licensing of patents and technologies. Integrated Biopharma Inc. values quality and customer relationships and offers comprehensive customer service as well as long-term partnerships with customers and partners.

The revenue cannot currently be calculated for Integrated Biopharma.

The profit cannot currently be calculated for Integrated Biopharma.

The P/E ratio cannot be calculated for Integrated Biopharma at the moment.

The P/S cannot be calculated for Integrated Biopharma currently.

The Eulerpool Quality Score for Integrated Biopharma is 2/10.

The ISIN of Integrated Biopharma is US45811V1052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Integrated Biopharma is 120093. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Integrated Biopharma is INBP. The ticker symbol is used to trade Integrated Biopharma shares on the stock exchange.

Integrated Biopharma paid dividends every year for the past 0 years.

Integrated Biopharma is assigned to the 'Non-cyclical consumption' sector.

The dividends of Integrated Biopharma are distributed in USD.

Fair ValueTerminal
0.15 USD
Over-/UndervaluationTerminal
Fairly valued
Industry
Personal Products
Number of shares
Employees
Revenue per Employee
355,248.37 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Oct 30, 1996
ISIN
US45811V1052
Cusip
45811V105
Sedol
2408594
Market capitalization
5.84 M USDMicro Cap
52-Week Range
0.15–0.38USD
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
1.18
P/B Ratio
0.29
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
3.95 %
Gross Margin
10.23 %
EBIT Margin
3.72 %
Net Margin
1.49 %
EPS (Earnings Per Share)
0.03 USD
Net Debt / EBIT
-1.71
Debt/Equity
0.01
Last updated Sep 27, 2026, 5:54 PM

Integrated Biopharma Ticker

OTC · INBPOTC · INBP

Integrated Biopharma FIGI

INBP:US · BBG000CPQS00INBP:PQ · BBG000CPQZD0INBP:UV · BBG000CPR064